Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. Founded in 1995, Depomed has successfully executed on strategy of acquiring, integrating and growing differentiated therapeutic products and building each into a strong market presence. The result is a broad portfolio of pain and neurology specialty pharmaceuticals currently comprised of five FDA-approved products. These include Gralise¬ for the management of Postherpetic Neuralgia (PHN), Cambia¬ for the acute treatment of migraine attacks, Zipsor¬ for the relief of mild to moderate acute pain, Lazanda¬ for the management of breakthrough pain in cancer patients and our most recent addition, the companyÍs flagship asset, the NUCYNTA¬ franchise. Acquired in April 2015 and re-launched in June 2015, the NUCYNTA franchise includes NUCYNTA¬ ER for the extended management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN) and NUCYNTA¬ for immediate management of moderate to severe acute pain in adults. Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform¬. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. The companyÍs Acuform technology is currently being used in four marketed drugs, including Gralise. DepomedÍs successful execution on strategy and has resulted in solid product revenue growth over the past three years. Located in Newark, California in the East Bay of San Francisco, Depomed is listed on the NASDAQ market under the ticker DEPO and employs approximately 500 people, of which approximately 350 are part of the Commercial organization. Depomed is an AA/EEO/Veterans/Disabled employer.